	US 11,939,359 B2
	Mutant pore
Lakmal Jayasinghe, Oxford (GB); Mark Bruce, Oxford (GB); Luke McNeill, Oxford (GB); Ramiz Iqbal Nathani, Oxford (GB); Pratik Raj Singh, Oxford (GB); Neil Roger Wood, Oxford (GB); and Stephen Robert Young, Oxford (GB)
Assigned to Oxford Nanopore Technologies PLC, Oxford (GB)
Filed by Oxford Nanopore Technologies PLC, Oxford (GB)
Filed on Jul. 26, 2021, as Appl. No. 17/384,889.
Application 17/384,889 is a continuation of application No. 16/091,746, granted, now 11,104,709, previously published as PCT/GB2017/050961, filed on Apr. 6, 2017.
Claims priority of application No. 1605899 (GB), filed on Apr. 6, 2016; and application No. 1608274 (GB), filed on May 11, 2016.
Prior Publication US 2022/0064230 A1, Mar. 3, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 35/62 (2006.01); C07K 14/435 (2006.01)

CPC C07K 14/43536 (2013.01) [A61K 35/62 (2013.01)]

14 Claims

1. An apparatus comprising a transmembrane protein pore inserted into an in vitro membrane, wherein the transmembrane protein pore comprises at least one mutant lysenin monomer comprising a variant of the sequence shown set forth in SEQ ID NO: 2, wherein the variant comprises the K45T/R amino acid substitution.